Business Context and Reporting Period
This Form 8-K Current Report was filed by Intellia Therapeutics, Inc. on September 25, 2025. The filing primarily discloses positive longer-term Phase 1 clinical data for the investigational CRISPR-based gene editing therapy nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). The report also provides an update on the ongoing Phase 3 MAGNITUDE-2 trial.
Key Financial Metrics
This filing is a current report regarding clinical developments and does not contain financial statements. Consequently, the document does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors should refer to the company's most recent Form 10-K or 10-Q for financial data.
Material Changes and Clinical Data
The filing details significant clinical milestones for nex-z as of the data cutoff date of April 11, 2025:
- TTR Reductions: In patients receiving a one-time dose of 0.3 mg/kg or higher (n=33), the mean serum TTR reduction at 24 months was 92% (mean absolute level 17.3 µg/mL). Among 12 patients with 36 months of follow-up, the mean reduction was 90% (mean absolute level 20 µg/mL).
- Clinical Outcomes: Favorable trends indicating stability or improvement were observed in most patients. Among 18 patients with 24-month assessments, 72% showed clinically meaningful improvements (≥4 points) in the modified Neuropathy Impairment Score +7 (mNIS+7).
- Secondary Endpoints: Mean values for mBMI, QoL-DN, and NfL trended toward disease improvement. 89% of patients showed improvement or stability in polyneuropathy disability (PND) scores through 24 months.
- Safety Profile: The therapy was generally well tolerated. The most common adverse events were mild or moderate infusion-related reactions. Three participants experienced Grade ≥3 liver enzyme elevations, which were asymptomatic and resolved spontaneously without intervention.
Guidance, Outlook, and Risks
Phase 3 MAGNITUDE-2 Trial Update:
- The trial is a randomized, double-blind, placebo-controlled study evaluating a single 55 mg infusion of nex-z in approximately 50 patients.
- Dosing began in April 2025, with enrollment completion expected in the first half of 2026.
- Intellia anticipates submitting a biologics license application (BLA) for ATTRv-PN by 2028.
Risks and Contingencies:
The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties regarding regulatory approvals, the ability to protect intellectual property, reliance on collaborations (specifically with Regeneron Pharmaceuticals, Inc.), and the possibility that clinical results may not be predictive of future outcomes or lead to successful commercialization.
Investor Verification Checklist
- Verify the specific inclusion/exclusion criteria for the 33 patients in the 24-month TTR reduction cohort to understand the patient population profile.
- Confirm the current enrollment status and patient screening rates for the Phase 3 MAGNITUDE-2 trial against the H1 2026 completion target.
- Review the most recent Form 10-Q or 10-K to assess cash runway and liquidity, as this 8-K contains no financial data.
- Monitor the status of the collaboration agreement with Regeneron Pharmaceuticals, Inc., as noted in the risk factors.
- Track the resolution of the three Grade ≥3 liver enzyme elevation cases to ensure no long-term sequelae emerge in future data reads.